Stock Screener
Stock Research
Delisted Stocks
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

CytoDyn Shares Outstanding 2010-2024 | CYDY

CytoDyn shares outstanding from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  
CytoDyn Annual Shares Outstanding
(Millions of Shares)
2024 970
2023 837
2022 677
2021 588
2020 421
2019 272
2018 175
2017 138
2016 95
2015 58
2014 47
2013 30
2012 25
2011 21
2010 19
2009 14
CytoDyn Quarterly Shares Outstanding
(Millions of Shares)
2024-05-31 970
2024-02-29 982
2023-11-30 959
2023-08-31 924
2023-05-31 837
2023-02-28 832
2022-11-30 813
2022-08-31 788
2022-05-31 677
2022-02-28 696
2021-11-30 663
2021-08-31 633
2021-05-31 588
2021-02-28 578
2020-11-30 578
2020-08-31 556
2020-05-31 421
2020-02-29 432
2019-11-30 389
2019-08-31 365
2019-05-31 272
2019-02-28 296
2018-11-30 259
2018-08-31 219
2018-05-31 175
2018-02-28 178
2017-11-30 158
2017-08-31 152
2017-05-31 138
2017-02-28 142
2016-11-30 136
2016-08-31 124
2016-05-31 95
2016-02-29 105
2015-11-30 84
2015-08-31 72
2015-05-31 58
2015-02-28 59
2014-11-30 56
2014-08-31 56
2014-05-31 47
2014-02-28 55
2013-11-30 45
2013-08-31 31
2013-05-31 30
2013-02-28 30
2012-11-30 30
2012-08-31 29
2012-05-31 25
2012-02-29 25
2011-11-30 22
2011-08-31 22
2011-05-31 21
2011-02-28 22
2010-11-30 21
2010-08-31 20
2010-05-31 19
2010-02-28 19
2009-11-30 20
2009-08-31 18
2009-05-31 14
2009-02-28 15
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.193B $0.000B
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $88.286B 35.17
Takeda Pharmaceutical (TAK) Japan $46.614B 9.33
Merck (MKGAF) Germany $23.031B 25.13
Astellas Pharma (ALPMY) Japan $21.569B 25.91
Sandoz Group AG (SDZNY) Switzerland $18.132B 0.00
Summit Therapeutics (SMMT) United States $16.527B 0.00
United Therapeutics (UTHR) United States $15.915B 16.44
Shionogi (SGIOY) Japan $13.333B 12.77
Neurocrine Biosciences (NBIX) United States $11.706B 35.02
Catalent (CTLT) United States $10.940B 0.00
Orion OYJ (ORINY) Finland $7.664B 31.21
Revolution Medicines (RVMD) United States $7.326B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.805B 7.22
Ionis Pharmaceuticals (IONS) United States $6.009B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.660B 0.00
Madrigal Pharmaceuticals (MDGL) United States $4.644B 0.00
Corcept Therapeutics (CORT) United States $4.522B 38.30
Crinetics Pharmaceuticals (CRNX) United States $4.048B 0.00
Dyne Therapeutics (DYN) United States $3.476B 0.00
PTC Therapeutics (PTCT) United States $2.897B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.585B 14.91
Arrowhead Pharmaceuticals (ARWR) United States $2.439B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.368B 18.82
Recursion Pharmaceuticals (RXRX) United States $2.016B 0.00
Soleno Therapeutics (SLNO) United States $1.896B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.776B 0.00
Xencor (XNCR) United States $1.595B 0.00
Harrow (HROW) United States $1.569B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.568B 0.00
Cassava Sciences (SAVA) United States $1.529B 0.00
Ardelyx (ARDX) United States $1.497B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.425B 0.00
ARS Pharmaceuticals (SPRY) United States $1.407B 0.00
Ocular Therapeutix (OCUL) United States $1.369B 0.00
Indivior (INDV) United States $1.368B 6.28
Collegium Pharmaceutical (COLL) United States $1.239B 7.11
Evotec AG (EVO) Germany $1.237B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.213B 0.00
Enliven Therapeutics (ELVN) United States $1.139B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.024B 0.00
Relay Therapeutics (RLAY) United States $0.991B 0.00
Bioventus (BVS) United States $0.895B 29.08
Cronos Group (CRON) Canada $0.837B 0.00
USANA Health Sciences (USNA) United States $0.721B 13.23
Savara (SVRA) United States $0.698B 0.00
Pacira BioSciences (PCRX) United States $0.661B 6.26
Ironwood Pharmaceuticals (IRWD) United States $0.649B 40.60
Exscientia (EXAI) United Kingdom $0.641B 0.00
Tourmaline Bio (TRML) United States $0.637B 0.00
ProKidney (PROK) United States $0.591B 0.00
4D Molecular Therapeutics (FDMT) United States $0.570B 0.00
Foghorn Therapeutics (FHTX) United States $0.536B 0.00
Silence Therapeutics (SLN) United Kingdom $0.522B 0.00
OmniAb (OABI) United States $0.500B 0.00
Siga Technologies (SIGA) United States $0.495B 5.93
Altimmune (ALT) United States $0.484B 0.00
Aquestive Therapeutics (AQST) United States $0.455B 0.00
Sage Therapeutics (SAGE) United States $0.438B 0.00
KalVista Pharmaceuticals (KALV) United States $0.432B 0.00
Xeris Biopharma Holdings (XERS) United States $0.422B 0.00
Verve Therapeutics (VERV) United States $0.420B 0.00
Elite Pharmaceuticals (ELTP) United States $0.416B 38.90
Larimar Therapeutics (LRMR) United States $0.404B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.394B 0.00
Lyell Immunopharma (LYEL) United States $0.389B 0.00
Zevra Therapeutics (ZVRA) United States $0.385B 0.00
Organogenesis (ORGO) United States $0.374B 0.00
Eliem Therapeutics (ELYM) United States $0.335B 0.00
Korro Bio (KRRO) United States $0.323B 0.00
Esperion Therapeutics (ESPR) United States $0.322B 0.00
Aldeyra Therapeutics (ALDX) United States $0.319B 0.00
Heron Therapeutics (HRTX) United States $0.311B 0.00
Lexeo Therapeutics (LXEO) United States $0.295B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.282B 0.00
Akebia Therapeutics (AKBA) United States $0.280B 0.00
ESSA Pharma (EPIX) Canada $0.276B 0.00
Avita Medical (RCEL) United States $0.275B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.259B 0.00
Nature's Sunshine Products (NATR) United States $0.250B 17.11
Black Diamond Therapeutics (BDTX) United States $0.249B 0.00
Nanobiotix S.A (NBTX) France $0.233B 0.00
Acrivon Therapeutics (ACRV) United States $0.225B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.222B 0.00
Pyxis Oncology (PYXS) United States $0.221B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.218B 0.00
Nektar Therapeutics (NKTR) United States $0.204B 0.00
Profound Medical (PROF) Canada $0.192B 0.00
Telomir Pharmaceuticals (TELO) United States $0.191B 0.00
MediWound (MDWD) Israel $0.180B 0.00
Innate Pharma SA (IPHYF) France $0.180B 0.00
Galectin Therapeutics (GALT) United States $0.165B 0.00
Achieve Life Sciences (ACHV) Canada $0.152B 0.00
Cardiol Therapeutics (CRDL) Canada $0.148B 0.00
VAXART, INC (VXRT) United States $0.143B 0.00
Context Therapeutics (CNTX) United States $0.139B 0.00
Century Therapeutics (IPSC) United States $0.130B 0.00
Incannex Healthcare (IXHL) Australia $0.130B 0.00
Prelude Therapeutics (PRLD) United States $0.122B 0.00
Fractyl Health (GUTS) United States $0.121B 0.00
Assertio Holdings (ASRT) United States $0.116B 20.33
Journey Medical (DERM) United States $0.113B 0.00
Regulus Therapeutics (RGLS) United States $0.103B 0.00
OptiNose (OPTN) United States $0.103B 0.00
Relmada Therapeutics (RLMD) United States $0.099B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.095B 0.00
Citius Pharmaceuticals (CTXR) United States $0.093B 0.00
AlloVir (ALVR) United States $0.090B 0.00
CASI Pharmaceuticals (CASI) China $0.089B 0.00
Karyopharm Therapeutics (KPTI) United States $0.088B 0.00
Aclaris Therapeutics (ACRS) United States $0.084B 0.00
Arch Biopartners (ACHFF) Canada $0.083B 0.00
PMV Pharmaceuticals (PMVP) United States $0.077B 0.00
Metagenomi (MGX) United States $0.076B 0.00
Swiftmerge Acquisition (IVCP) United States $0.076B 370.33
Verrica Pharmaceuticals (VRCA) United States $0.072B 0.00
Nutriband (NTRB) United States $0.070B 0.00
Champions Oncology (CSBR) United States $0.065B 0.00
Vivani Medical (VANI) United States $0.062B 0.00
SCYNEXIS (SCYX) United States $0.057B 0.00
Reneo Pharmaceuticals (RPHM) United States $0.054B 0.00
Mural Oncology (MURA) Ireland $0.052B 0.00
BioLineRx (BLRX) Israel $0.050B 0.00
Rafael Holdings (RFL) United States $0.048B 0.00
Gain Therapeutics (GANX) United States $0.047B 0.00
ProPhase Labs (PRPH) United States $0.043B 0.00
ElectroCore (ECOR) United States $0.043B 0.00
Carisma Therapeutics (CARM) United States $0.041B 0.00
Natural Alternatives (NAII) United States $0.040B 0.00
Inotiv (NOTV) United States $0.040B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.040B 0.00
DURECT (DRRX) United States $0.040B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Unicycive Therapeutics (UNCY) United States $0.039B 0.00
Protara Therapeutics (TARA) United States $0.038B 0.00
Enlivex Therapeutics (ENLV) Israel $0.034B 0.00
Surrozen (SRZN) United States $0.033B 0.00
Tempest Therapeutics (TPST) United States $0.033B 0.00
Oruka Therapeutics (ORKA) United States $0.029B 0.00
VYNE Therapeutics (VYNE) United States $0.028B 0.00
Lipocine (LPCN) United States $0.025B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.025B 0.00
Iterum Therapeutics (ITRM) Ireland $0.024B 0.00
MEI Pharma (MEIP) United States $0.019B 0.67
TherapeuticsMD (TXMD) United States $0.019B 0.00
Minerva Neurosciences (NERV) United States $0.019B 0.00
NRx Pharmaceuticals (NRXP) United States $0.018B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.017B 0.00
PolyPid (PYPD) Israel $0.017B 0.00
Lyra Therapeutics (LYRA) United States $0.016B 0.00
Cosmos Health (COSM) United States $0.015B 0.00
Mannatech (MTEX) United States $0.014B 0.00
Nuvilex (PMCB) United States $0.014B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.014B 0.00
Talphera (TLPH) United States $0.014B 0.00
Conduit Pharmaceuticals (CDT) United States $0.012B 0.00
Redhill Biopharma (RDHL) Israel $0.012B 0.00
Dominari Holdings (DOMH) United States $0.012B 0.00
GlycoMimetics (GLYC) United States $0.011B 0.00
Indaptus Therapeutics (INDP) United States $0.011B 0.00
Jaguar Animal Health (JAGX) United States $0.011B 0.00
TransCode Therapeutics (RNAZ) United States $0.011B 0.00
Vivos Therapeutics (VVOS) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
Addex Therapeutics (ADXN) Switzerland $0.010B 0.00
Aptorum Group (APM) United Kingdom $0.010B 0.00
Avalo Therapeutics (AVTX) United States $0.010B 0.00
Plus Therapeutics (PSTV) United States $0.009B 0.00
Molecular Templates (MTEM) United States $0.009B 0.00
Viracta Therapeutics (VIRX) United States $0.009B 0.00
Inhibikase Therapeutics (IKT) United States $0.009B 0.00
BioVie (BIVI) United States $0.007B 0.00
Mangoceuticals (MGRX) United States $0.007B 0.00
Traws Pharma (TRAW) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Alaunos Therapeutics (TCRT) United States $0.006B 0.00
Biomerica (BMRA) United States $0.006B 0.00
CERo Therapeutics Holdings (CERO) United States $0.005B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.005B 0.00
Oncternal Therapeutics (ONCT) United States $0.004B 0.00
Ainos (AIMD) United States $0.004B 0.00
Heatwurx (PCSA) United States $0.004B 0.00
TNF Pharmaceuticals (TNFA) United States $0.004B 0.00
Avenue Therapeutics (ATXI) United States $0.003B 0.09
Phio Pharmaceuticals (PHIO) United States $0.003B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Bio-Path Holdings (BPTH) United States $0.002B 0.00
Petros Pharmaceuticals (PTPI) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.002B 0.00
Qualigen Therapeutics (QLGN) United States $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
InMed Pharmaceuticals (INM) Canada $0.002B 0.00
SHINECO (SISI) China $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.001B 0.00
Aditxt (ADTX) United States $0.001B 0.00
PainReform (PRFX) Israel $0.000B 0.00
China SXT Pharmaceuticals (SXTC) China $0.000B 0.00
Qilian Holding Group (BGM) China $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 4.15
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 38.56